|
|
Profile
|
Delegates :
Kensei Tsuzaka, M.D.&Ph.D. |
|
Incorporated :
June 2 , 2010 |
Paid in Capital :
52 Million yen |
Employees :
3 人 |
Address :
Room#505, Yamaguchi Bldg. 4-38-22 Honcho, Funabashi CHIBA
〒273-0005
|
TEL/FAX :
+81-47-441-0017 / +81-47-441-0018 |
URL：
http://www.kayteebio-english.com/ |
Attachment :
 Kaytee_Bio_Profile_April_2016.pdf [ 398KiB ] |
Mission/Background :
We aim at overcoming diseases by developing and applying brand new diagnostic and treatment methods.Recently, the treatment of the autoimmune diseases including rheumatoid arthritis (RA) has advanced rapidly because of the appearance of the biologics reagents. However, such an advanced treatment has not been thought a fundamental treatment yet, and every patient has the hope for a further, new treatment. Moreover, the diagnostic product for the early diagnosis for RA is immediately hoped because the early diagnosis is an important tool to treat patient at the early stage. Our company aims to contribute to the society by developing the new treatment called fundamental one and diagnostic product related to early diagnosis. |
|
Technology & Business
|
We have developed a new diagnostic product for RA using a new disease-related protein, short-talin that is detected specifically in RA patients. Also we have developed a new therapeutic procedure for RA using blockade of the short-talin and the Talin Protease inhibitors. We have discovered that the antibody to the Talin Proteinase could inhibit the cleavage of talin to the short-talin. Also we have found that a unique
peptide could prevent this cleavage. Now we are planning to develop a medicine for RA treatment using the Talin Proteinase inhibitor and the unique peptide against the cleavage site of short-talin to suppress the expression of short-talin.
|
|
Products & Service
|
Products & Service Name
|
Stage
|
Outline
|
Milestone
|
BiologicMate
|
Phase2
|
BiologicMate that can predict the efficacy of the biologics reagents by ADAMTS5 gene expression in RA.
|
To distribute BiologicMate globally
|
Talin Test
|
Phase2
|
a new diagnostic product for RA using a new disease-related protein, short-talin
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Highlights
|
We begin the RA biologics prediction diagnosis using BiologicMate from this September in Japan.
|
|
Alliance strategy
|
We are searching an alliance partner for the development of the medicine using the inhibitors of Talin Protease or the blockage of the short-talin expression.
|
|
|